EasySep™ Human Pan-ILC Enrichment Kit

Immunomagnetic negative selection cell enrichment kit

New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more

EasySep™ Human Pan-ILC Enrichment Kit

Immunomagnetic negative selection cell enrichment kit

From: 1,000 USD
Catalog #
(Select a product)
Immunomagnetic negative selection cell enrichment kit
Add to Wish List

Product Advantages


  • Fast, easy-to-use and column-free

  • Untouched, viable cells

  • Facilitates rapid flow sorting of ILCs

What's Included

  • EasySep™ Human Pan-ILC Enrichment Kit (Catalog #17975)
    • EasySep™ Human Pan-ILC Enrichment Cocktail, 0.5 mL
    • EasySep™ Dextran RapidSpheres™ 50103, 1 mL
  • RoboSep™ Human Pan-ILC Enrichment Kit (Catalog #17975RF)
    • EasySep™ Human Pan-ILC Enrichment Cocktail, 0.5 mL
    • EasySep™ Dextran RapidSpheres™ 50103, 1 mL
    • RoboSep™ Buffer (Catalog #20104)
    • RoboSep™ Filter Tips (Catalog #20125)
Products for Your Protocol

Overview

The EasySep™ Human Pan-ILC Enrichment Kit is designed to enrich Group 1, 2, and 3 Innate Lymphoid Cells (ILC1, 2, and 3) from leukapheresis products by immunomagnetic negative selection. Unwanted cells are targeted for removal by Tetrameric Antibody Complexes directed against non-ILCs and dextran-coated magnetic particles (RapidSpheres™). Labeled cells are separated using an EasySep™ magnet without the use of columns. Unwanted cells remain in the tube as enriched ILCs are simply poured off into a new tube. Isolated cells are immediately available for flow sorting and other downstream applications.
Magnet Compatibility
• “The Big Easy” EasySep™ Magnet (Catalog #18001)
• Easy 50 EasySep™ Magnet (Catalog #18002)
• EasyEights™ EasySep™ Magnet (Catalog #18103)
• RoboSep™-S (Catalog #21000)
Subtype
Cell Isolation Kits
Cell Type
Innate Lymphoid Cells
Species
Human
Sample Source
Leukapheresis, PBMC
Selection Method
Negative
Application
Cell Isolation
Brand
EasySep, RoboSep
Area of Interest
Immunology

Data Figures

Typical EasySep™ Human Pan-ILC Enrichment Profile

Figure 1. Typical EasySep™ Human Pan-ILC Enrichment Profile

Starting with fresh leukapheresis samples, the total ILC content (Lin-CD45+CD127+) of the enriched fraction typically ranges from 17 - 85%. In the above example, the percentages of ILCs in the start and final enriched fractions are 0.09% and 45% (or 0.1% and 54% of CD45+ cells), respectively.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
17975
Lot #
All
Language
English
Catalog #
17975RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
17975
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
17975
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
17975RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
17975RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
17975RF
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Publications (1)

Endothelin-A Receptor Antagonist Alleviates Allergic Airway Inflammation via the Inhibition of ILC2 Function. X. Zhang et al. Frontiers in immunology 2022

Abstract

Allergic airway inflammation is a universal airway disease that is driven by hyperresponsiveness to inhaled allergens. Group 2 innate lymphoid cells (ILC2s) produce copious amounts of type 2 cytokines, which lead to allergic airway inflammation. Here, we discovered that both peripheral blood of human and mouse lung ILC2s express the endothelin-A receptor (ETAR), and the expression level of ETAR was dramatically induced upon interleukin-33 (IL-33) treatment. Subsequently, both preventive and therapeutic effects of BQ123, an ETAR antagonist, on allergic airway inflammation were observed, which were associated with decreased proliferation and type 2 cytokine productions by ILC2s. Furthermore, ILC2s from BQ123 treatment were found to be functionally impaired in response to an interleukin IL-33 challenged. And BQ123 treatment also affected the phosphorylation level of the extracellular signal-regulated kinase (ERK), as well as the level of GATA binding protein 3 (GATA3) in activated ILC2s. Interestingly, after BQ123 treatment, both mouse and human ILC2s in vitro exhibited decreased function and downregulation of ERK signaling and GATA3 stability. These observations imply that ETAR is an important regulator of ILC2 function and may be involved in ILC2-driven pulmonary inflammation. Therefore, blocking ETAR may be a promising therapeutic strategy for allergic airway inflammation.
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more